Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiationXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either therapyXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab; (Note: pregnancy testing should be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumabXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with taselisibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with tremelimumab and MEDI3617Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with ruxolitinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide or pomalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiationXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ficlatuzumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bavituximabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ramucirumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinibXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin; these potential risks may also apply to other agents used in this study.Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PLX3397 and sirolimusXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ponatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxelXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimusXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with natalizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with WDVAXXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinuedXx_NEWLINE_xXPersons who are pregnant are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab or nivolumab; a negative serum pregnancy test is required prior to study entryXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BVD523Xx_NEWLINE_xXMales and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab, gemcitabine, and oxaliplatinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with abemaciclib; a negative serum pregnancy test is required for women of childbearing potential prior to study entryXx_NEWLINE_xXBreastfeeding should be discontinuedXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treatedXx_NEWLINE_xXEXPANDED ACCESS COHORT: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib and LY2874455Xx_NEWLINE_xXActive pregnancy or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gefitinib or osimertinib agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LY3022855; these potential risks may also apply to the other agents used in this studyXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXLactating or breastfeeding women are excluded, breastfeeding should be discontinued prior to being treated with AZD1775; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)Xx_NEWLINE_xXPregnant or breastfeeding women; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine or IMGN853Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IMA950-poly-ICLC vaccineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemoembolic agentXx_NEWLINE_xXBreastfeeding should be discontinued if the mother wishes to participate in this studyXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control \r\n* Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agentXx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapyXx_NEWLINE_xXPregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-DecXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GBM6-AD-poly vaccineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiationXx_NEWLINE_xXPregnant or nursing patients will be excluded from the study; breastfeeding should be discontinued if the mother is treated with sunitinib or everolimusXx_NEWLINE_xXPatients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexorXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PTX-200; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant or lactating females; breastfeeding should be discontinued if the mother is treated with carfilzomib/lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CombotoxXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pyrimethamineXx_NEWLINE_xXPregnant women are excluded from this study because topotecan and temozolomide are class D agents with the potential for teratogenic or abortifacient effects and because the effects of M7824 on the developing human fetus are currently unknown. In addition, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with topotecan, temozolomide or M7824, breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansineXx_NEWLINE_xXBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib, breastfeeding should be discontinued if the mother is treated with olaparibXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100 + SEL-110Xx_NEWLINE_xXActive pregnancy or breast-feeding: pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M7824Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201Xx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with clofarabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclaxXx_NEWLINE_xXPregnant and/or breastfeeding women or unable to maintain use of contraception while on study and for 30 days after the last dose of study drug; breastfeeding should be discontinued if the mother is treated with ONC201Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with EGF816 and gefitinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapyXx_NEWLINE_xXBreastfeeding should be discontinued until 6 weeks after the last administration of study drugXx_NEWLINE_xXPregnant women are excluded from this study because INCB039110, dabrafenib, and trametinib may have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the mother being treated with the study drugs.Xx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant women are excluded from this study; in nursing mothers, breastfeeding should be discontinuedXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXBreastfeeding must be discontinued if the mother is treated with pembrolizumabXx_NEWLINE_xXPregnant women are excluded from this study because meclizine is class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with meclizine, breastfeeding should be discontinued if the mother is treated with meclizine.Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with fostamatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with DAC-THUXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with trametinibXx_NEWLINE_xXBreastfeeding should be discontinued if the mother wishes to participate in this studyXx_NEWLINE_xXPregnant women, or women who intend to become pregnant during the study, are excluded from this study; breastfeeding should be discontinued if the mother is treated on studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD8186; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IORTXx_NEWLINE_xXFemale patients who are breastfeeding; breastfeeding should be discontinued if the mother is treated with Pexa-VecXx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with E6 TCRXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either of those agents; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either dabrafenib, trametinib, or the combination of dabrafenib and trametinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lamivudineXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoidedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or MK-3475 (pembrolizumab)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding women are excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled in the trialXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXFemale participants pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with the study drugsXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).Xx_NEWLINE_xXPregnancy or lactation period; note: a negative pregnancy test is required for women of childbearing potential; women who are postmenopausal (age-related amenorrhea >= 12 consecutive months or follicle-stimulating hormone [FSH] > 40 milli international units per milliliter [mIU/ml]), or who had undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing; if necessary to confirm postmenopausal status a FSH level will be included at screening; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with avelumab; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with avelumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1127 (varlilumab) or nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SBRTXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184 and nivolumabXx_NEWLINE_xXPregnancy and breastfeeding: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus and fosbretabulinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-2Xx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cisplatin or radiation on this trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant or lactating females; breastfeeding should be discontinued if the mother is treated with isatuximabXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with intraperitoneal interferonsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinibXx_NEWLINE_xXPregnant and/or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinibXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with durvalumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocolXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-DecXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100Xx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with LMB-100; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cesium 131Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated lenvatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101 and/or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IRX5183Xx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the\r\nmother is treated with ramucirumab; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib and not resumed until at least 2 weeks after the final doseXx_NEWLINE_xXPregnancy or breast feeding; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; breastfeeding must be discontinued if the mother is treated with pembrolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agentXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with pomalidomide; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazoleXx_NEWLINE_xXSubject is pregnant or nursing; breastfeeding should be discontinued if the mother is treated with ACY-1215Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumabXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued prior to study entryXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamineXx_NEWLINE_xXPregnant or nursing females are to be excluded; breastfeeding should be discontinued if the mother is treated with taladegibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemotherapy and/or radiationXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosineXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is being treated on this trial.Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdRXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued for the duration of active study therapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temozolomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with indium In 111 (111In-) and 90Y-basiliximab-DOTAXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-afliberceptXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued while on study; patients who become pregnant while on study will be removed from the study once the pregnancy is confirmedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugsXx_NEWLINE_xXPregnancy or breast feeding; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; breastfeeding must be discontinued if the mother is treated with MK-3475Xx_NEWLINE_xXExcluded patient groups:\r\n* Pregnant women are excluded from this study; breastfeeding women will not be included in the study\r\n* Human immunodeficiency virus (HIV)-seropositive patients are excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXMust not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated azacitidineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for at least 3 months thereafter; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cisplatinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdRXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumabXx_NEWLINE_xXBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lapatinib of bevacizumab, breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapyXx_NEWLINE_xXA nursing mother unwilling to discontinue breastfeeding; breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiationXx_NEWLINE_xXPregnant women are excluded from this study. Breastfeeding should be discontinued if the mother is treated with cenersenXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CPI-613Xx_NEWLINE_xXPregnant or planning pregnancy within the next 6 months, or breastfeeding; breastfeeding should be discontinued if the mother is treated with 5-fluorouracilXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenvatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant or breastfeeding (Note: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant women or women who expect to conceive a child are excluded from the study; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX970); these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232 through 1 week after receiving the last dose of study drugXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavirXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolledXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MylotargXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with navitoclax and vistusertibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparibXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranibXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agentsXx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabineXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinibXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with sirolimusXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolledXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinibXx_NEWLINE_xXPregnant women are excluded from ECP; breastfeeding should be discontinued if the mother is treated with methoxsalen; pregnancy will be evaluated prior to the initiation of ECPXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with indenoisoquinolinesXx_NEWLINE_xXPregnancy or nursing or unwilling to take adequate birth control during therapy \r\n* NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1401 or CDX-301 and poly-ICLCXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803Xx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding must be discontinued for eligibilityXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 5-FU/capecitabine; pregnancy testing will be completed on all female participants of child-bearing potential by urine analysisXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD6244Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TPI 287Xx_NEWLINE_xXPregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with HDACI and radiation; women of childbearing age and men sexually active with woman of childbearing age must agree to an acceptable method of birth control (double barrier) while on studyXx_NEWLINE_xXPatient is pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is participating in this studyXx_NEWLINE_xXPregnancy, nursing, or unwilling to take adequate birth control during therapy\r\n* NOTE: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with INCB024360 and MELITAC 12.1Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsinXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with PF-04449913Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostatXx_NEWLINE_xXPregnant women are excluded from this study; women who are breast feeding their infants should discontinue this practice if the mother is treated with ruxolitinibXx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinibXx_NEWLINE_xXPregnant/nursing women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oxaliplatin or mitomycin CXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-12; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXBreastfeeding should be discontinuedXx_NEWLINE_xXFemale participants pregnant or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide; these potential risks may also apply to other agents used in this study; lactating females must agree not to breast feed while taking lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AZD1775 and cisplatin; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888Xx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with proton radiotherapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to beginning treatmentXx_NEWLINE_xXBreastfeeding should be discontinued until 6 weeks after the last administration of study drugXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquineXx_NEWLINE_xXPregnant or lactating women are excluded; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232Xx_NEWLINE_xXPregnant and nursing women; breastfeeding should be discontinued if the mother is treated with combination ETBX-011, ETBX-051, ETBX-061Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued while the mother is receiving protocol therapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this research protocolXx_NEWLINE_xXPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)Xx_NEWLINE_xXPregnant or lactating females; breastfeeding should be discontinued if the mother is treated with pembrolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pIL-12 EP + pembrolizumabXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued prior to entry onto the studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib; potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8327Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin and gemcitabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPI-145Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to starting study treatmentXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; breastfeeding should be discontinued if the mother is treated on this study with idelalisib and ofatumumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents and/or radiationXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued upon start of protocol therapyXx_NEWLINE_xXSubjects who are pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with curcuminXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding must be discontinued if the mother is treated with sunitinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if patient wishes to participate in studyXx_NEWLINE_xXPHASE I: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib; potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPHASE II: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GSK1120212 and GSK2141795Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib and/or fulvestrantXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent, and for 30 days after discontinuation of therapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinibXx_NEWLINE_xXBreast-feeding should be discontinued if a nursing mother is to be treated on clinical trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a class D agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomideXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazoleXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued prior to participation of the mother on studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinued while the mother is taking study drug and for at least 28 days after discontinuation of study drugXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AMG 386Xx_NEWLINE_xXPregnant women are excluded from this study. mFOLFIRINOX is a regimen containing more than one chemotherapy agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with FOLFIRINOX, breastfeeding should be discontinued if the mother is treated with these agents. These potential risks may also apply to other agents used in this study.Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinibXx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostatXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated sorafenibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on either arm of the trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding is not allowed during study treatmentXx_NEWLINE_xXPregnant or nursing women or men/women of child-bearing potential who are unwilling to employ adequate contraception; breastfeeding should be discontinued if the mother is treated with FOLFOX-bevacizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sonidegibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this clinical trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumabXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with eltrombopagXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and eribulinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued at least two weeks prior to the start of PF-00299804 dosingXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with entinostatXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with E7389Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ganetespib; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXLactating or pregnant; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXPregnant or nursing; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy\r\n* Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775/belinostatXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-1775Xx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with paclitaxelXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocolXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study because tretinoin is a retinoid derivative agent with the potential for teratogenic or abortifacient effects; because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with tretinoin, breastfeeding should be discontinued if the mother is treated with tretinoin; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated in this protocolXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with sEphB4-HSAXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MPDL3280AXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostatXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206 and/or dinaciclibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CUDC-907; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral tetrahydrouridine- decitabine [THU-Dec])Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib R-ICEXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MVA-brachyury-TRICOM; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnancy or lactation; breastfeeding should be discontinued if the mother is treated with this regimenXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pioglitazoneXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPatients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agentsXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with DMS612Xx_NEWLINE_xXBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus or bevacizumab, breastfeeding should be discontinued if the mother is treated on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BMN 673 or AT13387Xx_NEWLINE_xXPregnant women (admittedly, an unlikely event) are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ivabradineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued by nursing mothers who agree to participate in the studyXx_NEWLINE_xXFemale subjects who are pregnant, have a positive serum human chorionic gonadotrophin (hCG), or are lactating and intend to breast feed a child; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NEPAXx_NEWLINE_xXPregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trialXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agentsXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7Xx_NEWLINE_xXPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naltrexoneXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinibXx_NEWLINE_xXPatients who are pregnant or nursing are excluded; breastfeeding should be discontinued if the mother is treated with cytotoxic chemotherapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with isoquercetin; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant or nursing women; breastfeeding should be discontinued if the mother is treated with INO-8000Xx_NEWLINE_xXWomen who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated\r\nwith simvastatinXx_NEWLINE_xXPregnant or lactating women; breastfeeding should be discontinued if the mother is treated with aspirin; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediatelyXx_NEWLINE_xXPregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with the vaccineXx_NEWLINE_xXWomen who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with simvastatinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this vaccineXx_NEWLINE_xXRECIPIENT: Pregnant women and women who are lactating. The risks of CMV?MVA?Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this studyXx_NEWLINE_xXWomen who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with aspirinXx_NEWLINE_xXPregnant or breast feeding; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MerivaXx_NEWLINE_xXPregnant or lactating women are excluded from this study; breastfeeding must be discontinued for the duration of study participation and for 56 days after the last dose of the study agentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirinXx_NEWLINE_xXWomen must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with iloprostXx_NEWLINE_xXWomen who are pregnant or breastfeeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pravastatinXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excludedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this study agentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with berberine; women are considered to be of child-bearing potential if they are not surgically sterile or under the age 65 and have menstruated within the last two yearsXx_NEWLINE_xXPregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naproxenXx_NEWLINE_xXParticipants who are pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Polyphenon EXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drugXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965Xx_NEWLINE_xXPregnant or lactating women; breastfeeding should be discontinued if the mother is treated with aspirin; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediatelyXx_NEWLINE_xXBreastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 64Cu-M5AXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this study; women who are breastfeeding are also excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding mothers are also excluded from this studyXx_NEWLINE_xXWomen who are pregnant or may become pregnant, as well as those women who are breastfeeding, will be excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother has been exposed to L-[methyl-11C]methionine; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SL-401 and azacitidineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with APR-246Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014Xx_NEWLINE_xXPregnant or lactating women; breastfeeding should be discontinued if the mother receives 18F-FdCydXx_NEWLINE_xXPregnant or lactating women: pregnant women are excluded from this study; breastfeeding should be discontinued for at least one day if the mother receives 68Ga-DOTATATEXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with ALAXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LB100Xx_NEWLINE_xXPregnant women are excluded. Breastfeeding should be discontinued if the mother is treated with LUM015.Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding must be discontinued.Xx_NEWLINE_xX